Ultra  ||| S:0 E:6 ||| FW
rapidly  ||| S:6 E:14 ||| FW
dissolving  ||| S:14 E:25 ||| FW
repaglinide  ||| S:25 E:37 ||| FW
nanosized  ||| S:37 E:47 ||| FW
crystals  ||| S:47 E:56 ||| NNS
prepared  ||| S:56 E:65 ||| VBN
via  ||| S:65 E:69 ||| IN
bottom-up  ||| S:69 E:79 ||| JJ
and  ||| S:79 E:83 ||| CC
top-down  ||| S:83 E:92 ||| JJ
approach ||| S:92 E:100 ||| NN
:  ||| S:100 E:102 ||| :
influence  ||| S:102 E:112 ||| NN
of  ||| S:112 E:115 ||| IN
food  ||| S:115 E:120 ||| NN
on  ||| S:120 E:123 ||| IN
pharmacokinetics  ||| S:123 E:140 ||| JJ
behavior  ||| S:140 E:149 ||| NN
The  ||| S:149 E:153 ||| DT
present  ||| S:153 E:161 ||| JJ
work  ||| S:161 E:166 ||| NN
was  ||| S:166 E:170 ||| VBD
undertaken  ||| S:170 E:181 ||| VBN
with  ||| S:181 E:186 ||| IN
the  ||| S:186 E:190 ||| DT
objectives  ||| S:190 E:201 ||| NNS
of  ||| S:201 E:204 ||| IN
improving  ||| S:204 E:214 ||| VBG
the  ||| S:214 E:218 ||| DT
dissolution  ||| S:218 E:230 ||| JJ
velocity ||| S:230 E:238 ||| NN
,  ||| S:238 E:240 ||| ,
related  ||| S:240 E:248 ||| VBN
oral  ||| S:248 E:253 ||| JJ
bioavailability ||| S:253 E:268 ||| NN
,  ||| S:268 E:270 ||| ,
and  ||| S:270 E:274 ||| CC
minimizing  ||| S:274 E:285 ||| VBG
the  ||| S:285 E:289 ||| DT
fasted ||| S:289 E:295 ||| NN
/ ||| S:295 E:296 ||| VBZ
fed  ||| S:296 E:300 ||| VBN
state  ||| S:300 E:306 ||| NN
variability  ||| S:306 E:318 ||| NN
of  ||| S:318 E:321 ||| IN
repaglinide ||| S:321 E:332 ||| NN
,  ||| S:332 E:334 ||| ,
a  ||| S:334 E:336 ||| DT
poorly  ||| S:336 E:343 ||| RB
water-soluble  ||| S:343 E:357 ||| JJ
anti-diabetic  ||| S:357 E:371 ||| JJ
active  ||| S:371 E:378 ||| JJ
by  ||| S:378 E:381 ||| IN
exploring  ||| S:381 E:391 ||| VBG
the  ||| S:391 E:395 ||| DT
principles  ||| S:395 E:406 ||| NNS
of  ||| S:406 E:409 ||| IN
nanotechnology ||| S:409 E:423 ||| NN
.  ||| S:423 E:425 ||| .
Nanocrystal  ||| S:425 E:437 ||| JJ
formulations  ||| S:437 E:450 ||| NNS
were  ||| S:450 E:455 ||| VBD
prepared  ||| S:455 E:464 ||| VBN
by  ||| S:464 E:467 ||| IN
both  ||| S:467 E:472 ||| DT
top-down  ||| S:472 E:481 ||| JJ
and  ||| S:481 E:485 ||| CC
bottom-up  ||| S:485 E:495 ||| JJ
approaches ||| S:495 E:505 ||| NNS
.  ||| S:505 E:507 ||| .
These  ||| S:507 E:513 ||| DT
approaches  ||| S:513 E:524 ||| NNS
were  ||| S:524 E:529 ||| VBD
compared  ||| S:529 E:538 ||| VBN
in  ||| S:538 E:541 ||| IN
light  ||| S:541 E:547 ||| NN
of  ||| S:547 E:550 ||| IN
their  ||| S:550 E:556 ||| PRP$
ability  ||| S:556 E:564 ||| NN
to  ||| S:564 E:567 ||| TO
provide  ||| S:567 E:575 ||| VB
the  ||| S:575 E:579 ||| DT
formulation  ||| S:579 E:591 ||| JJ
stability  ||| S:591 E:601 ||| NN
in  ||| S:601 E:604 ||| IN
terms  ||| S:604 E:610 ||| NNS
of  ||| S:610 E:613 ||| IN
particle  ||| S:613 E:622 ||| JJ
size ||| S:622 E:626 ||| NN
.  ||| S:626 E:628 ||| .
Soluplus®  ||| S:628 E:638 ||| NNP
was  ||| S:638 E:642 ||| VBD
used  ||| S:642 E:647 ||| VBN
as  ||| S:647 E:650 ||| IN
a  ||| S:650 E:652 ||| DT
stabilizer  ||| S:652 E:663 ||| NN
and  ||| S:663 E:667 ||| CC
Kolliphor™  ||| S:667 E:678 ||| NNP
E-TPGS  ||| S:678 E:685 ||| NNP
was  ||| S:685 E:689 ||| VBD
used  ||| S:689 E:694 ||| VBN
as  ||| S:694 E:697 ||| IN
an  ||| S:697 E:700 ||| DT
oral  ||| S:700 E:705 ||| JJ
absorption  ||| S:705 E:716 ||| JJ
enhancer ||| S:716 E:724 ||| NN
.  ||| S:724 E:726 ||| .
In  ||| S:726 E:729 ||| IN
vitro  ||| S:729 E:735 ||| JJ
dissolution  ||| S:735 E:747 ||| NN
profiles  ||| S:747 E:756 ||| NNS
were  ||| S:756 E:761 ||| VBD
investigated  ||| S:761 E:774 ||| VBN
in  ||| S:774 E:777 ||| IN
distilled  ||| S:777 E:787 ||| JJ
water ||| S:787 E:792 ||| NN
,  ||| S:792 E:794 ||| ,
fasted  ||| S:794 E:801 ||| NN
and  ||| S:801 E:805 ||| CC
fed  ||| S:805 E:809 ||| JJ
state  ||| S:809 E:815 ||| NN
simulated  ||| S:815 E:825 ||| VBZ
gastric  ||| S:825 E:833 ||| JJ
fluid ||| S:833 E:838 ||| NN
,  ||| S:838 E:840 ||| ,
and  ||| S:840 E:844 ||| CC
compared  ||| S:844 E:853 ||| VBN
with  ||| S:853 E:858 ||| IN
the  ||| S:858 E:862 ||| DT
pure  ||| S:862 E:867 ||| JJ
repaglinide ||| S:867 E:878 ||| NN
.  ||| S:878 E:880 ||| .
In  ||| S:880 E:883 ||| IN
vivo  ||| S:883 E:888 ||| JJ
pharmacokinetics  ||| S:888 E:905 ||| NN
was  ||| S:905 E:909 ||| VBD
performed  ||| S:909 E:919 ||| VBN
in  ||| S:919 E:922 ||| IN
both  ||| S:922 E:927 ||| PDT
the  ||| S:927 E:931 ||| DT
fasted  ||| S:931 E:938 ||| NN
and  ||| S:938 E:942 ||| CC
fed  ||| S:942 E:946 ||| JJ
state  ||| S:946 E:952 ||| NN
using  ||| S:952 E:958 ||| VBG
Wistar  ||| S:958 E:965 ||| JJ
rats ||| S:965 E:969 ||| NNS
.  ||| S:969 E:971 ||| .
Oral  ||| S:971 E:976 ||| JJ
hypoglycemic  ||| S:976 E:989 ||| JJ
activity  ||| S:989 E:998 ||| NN
was  ||| S:998 E:1002 ||| VBD
also  ||| S:1002 E:1007 ||| RB
assessed  ||| S:1007 E:1016 ||| VBN
in  ||| S:1016 E:1019 ||| IN
streptozotocin-induced  ||| S:1019 E:1042 ||| JJ
diabetic  ||| S:1042 E:1051 ||| JJ
rats ||| S:1051 E:1055 ||| NNS
.  ||| S:1055 E:1057 ||| .
Nanocrystals  ||| S:1057 E:1070 ||| NNP
TD-A  ||| S:1070 E:1075 ||| NNP
and  ||| S:1075 E:1079 ||| CC
TD-B  ||| S:1079 E:1084 ||| NNP
showed  ||| S:1084 E:1091 ||| VBD
19.86  ||| S:1091 E:1097 ||| CD
and  ||| S:1097 E:1101 ||| CC
25.67-fold  ||| S:1101 E:1112 ||| CD
increase  ||| S:1112 E:1121 ||| NN
in  ||| S:1121 E:1124 ||| IN
saturation  ||| S:1124 E:1135 ||| JJ
solubility ||| S:1135 E:1145 ||| NN
,  ||| S:1145 E:1147 ||| ,
respectively ||| S:1147 E:1159 ||| RB
,  ||| S:1159 E:1161 ||| ,
when  ||| S:1161 E:1166 ||| WRB
compared  ||| S:1166 E:1175 ||| VBN
with  ||| S:1175 E:1180 ||| IN
pure  ||| S:1180 E:1185 ||| JJ
repaglinide ||| S:1185 E:1196 ||| NN
.  ||| S:1196 E:1198 ||| .
Almost  ||| S:1198 E:1205 ||| RB
10  ||| S:1205 E:1208 ||| CD
( ||| S:1208 E:1209 ||| -LRB-
TD-A ||| S:1209 E:1213 ||| NNP
)  ||| S:1213 E:1215 ||| -RRB-
and  ||| S:1215 E:1219 ||| CC
15  ||| S:1219 E:1222 ||| CD
( ||| S:1222 E:1223 ||| -LRB-
TD-B ||| S:1223 E:1227 ||| NNP
) ||| S:1227 E:1228 ||| -RRB-
-fold  ||| S:1228 E:1234 ||| JJ
enhancement  ||| S:1234 E:1246 ||| NN
in  ||| S:1246 E:1249 ||| IN
the  ||| S:1249 E:1253 ||| DT
oral  ||| S:1253 E:1258 ||| JJ
bioavailability  ||| S:1258 E:1274 ||| NN
of  ||| S:1274 E:1277 ||| IN
nanocrystals  ||| S:1277 E:1290 ||| NN
was  ||| S:1290 E:1294 ||| VBD
observed  ||| S:1294 E:1303 ||| VBN
regardless  ||| S:1303 E:1314 ||| RB
of  ||| S:1314 E:1317 ||| IN
the  ||| S:1317 E:1321 ||| DT
fasted ||| S:1321 E:1327 ||| NN
/ ||| S:1327 E:1328 ||| VBZ
fed  ||| S:1328 E:1332 ||| VBN
state  ||| S:1332 E:1338 ||| NN
compared  ||| S:1338 E:1347 ||| VBN
to  ||| S:1347 E:1350 ||| TO
pure  ||| S:1350 E:1355 ||| JJ
repaglinide ||| S:1355 E:1366 ||| NN
.  ||| S:1366 E:1368 ||| .
Nanocrystal  ||| S:1368 E:1380 ||| JJ
formulations  ||| S:1380 E:1393 ||| NNS
also  ||| S:1393 E:1398 ||| RB
demonstrated  ||| S:1398 E:1411 ||| VBN
significant  ||| S:1411 E:1423 ||| JJ
( ||| S:1423 E:1424 ||| -LRB-
p    ||| S:1424 E:1426 ||| NNP
< ||| S:1426 E:1427 ||| SYM
0.001 ||| S:1428 E:1433 ||| NNP
)  ||| S:1433 E:1435 ||| -RRB-
hypoglycemic  ||| S:1435 E:1448 ||| JJ
activity  ||| S:1448 E:1457 ||| NN
with  ||| S:1457 E:1462 ||| IN
faster  ||| S:1462 E:1469 ||| JJR
onset  ||| S:1469 E:1475 ||| NN
( ||| S:1475 E:1476 ||| -LRB-
less  ||| S:1476 E:1481 ||| JJR
than  ||| S:1481 E:1486 ||| IN
30  ||| S:1486 E:1489 ||| CD
min ||| S:1489 E:1492 ||| CD
)  ||| S:1492 E:1494 ||| -RRB-
and  ||| S:1494 E:1498 ||| CC
prolonged  ||| S:1498 E:1508 ||| JJ
duration  ||| S:1508 E:1517 ||| NN
( ||| S:1517 E:1518 ||| -LRB-
up  ||| S:1518 E:1521 ||| RB
to  ||| S:1521 E:1524 ||| TO
8  ||| S:1524 E:1526 ||| CD
h ||| S:1526 E:1527 ||| CD
)  ||| S:1527 E:1529 ||| -RRB-
compared  ||| S:1529 E:1538 ||| VBN
to  ||| S:1538 E:1541 ||| TO
pure  ||| S:1541 E:1546 ||| JJ
repaglinide  ||| S:1546 E:1558 ||| NNS
( ||| S:1558 E:1559 ||| -LRB-
after  ||| S:1559 E:1565 ||| IN
60  ||| S:1565 E:1568 ||| CD
min ||| S:1568 E:1571 ||| NNS
;  ||| S:1571 E:1573 ||| :
up  ||| S:1573 E:1576 ||| RB
to  ||| S:1576 E:1579 ||| TO
4  ||| S:1579 E:1581 ||| CD
h ||| S:1581 E:1582 ||| NN
,  ||| S:1582 E:1584 ||| ,
respectively ||| S:1584 E:1596 ||| RB
) ||| S:1596 E:1597 ||| -RRB-
.  ||| S:1597 E:1599 ||| .
